Search | Clinical Trials Finder

Conditions: Cytomegalovirus Infection, Adenovirus Infection
Interventions: CMV/AdV specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Pain
Interventions: J-tip jet injection of 1% buffered lidocaine; Procedure
Lead sponsor: Norton Healthcare; Other
Eligibility: 8 Years to 15 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Prostate Cancer, Metastases, Pharmacokinetics
Interventions: Radium-223 chloride (BAY88-8223); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more

Conditions: Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
Interventions: Hepatitis A & B vaccine, Outreach, AIC, SEP; Biological · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 14 Years to 29 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoma, Soft Tissue
Interventions: BLZ-100; Drug
Lead sponsor: Blaze Bioscience Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: AVI-7100 versus placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: VRC-HIVMAB0102-00-AB; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fever
Interventions: Ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more

Conditions: Prostate Cancer
Interventions: DHA-paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 8
States / cities: Tucson, Arizona • Berkeley, California • Lexington, Kentucky + 5 more

Conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions: Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 9
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: LyphoMed; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rosemont, Illinois

Conditions: Oncology Patients Receiving Chemotherapy
Interventions: Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel; Drug
Lead sponsor: TerSera Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Worcester, Massachusetts

Conditions: Total Knee Arthroplasty
Interventions: Vancomycin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections, Depression, Substance-Related Disorders
Interventions: Cognitive Behavioral Therapy, Psychopharmacology; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Tampa, Florida • New York, New York

Conditions: Postoperative Nausea and Vomiting
Interventions: APD421, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Healthy Volunteers
Interventions: KINE-101, Placebo; Drug
Lead sponsor: Kine Sciences Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Herpes Simplex, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrophy, Geographic
Interventions: GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Testing the AVI-7100 Flu Drug in Healthy Volunteers

A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Vancomycin in TKAs

Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Study of APD421 as PONV Treatment (Prior Prophylaxis)

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

A First-in-Human Study of KINE-101 in Healthy Volunteers

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers